1 Introduction: Females are thought to have increased risk of developing posttraumatic headache 2 (PTH) following a traumatic head injury, or concussion. However, the processes underlying this 3 susceptibility remain unclear. We previously explored the development of PTH-like pain 4 behaviors in a novel rat model of mild closed head injury, along with the ability of sumatriptan 5 and an anti-calcitonin-gene-related peptide monoclonal antibody to ameliorate these behaviors. 6
Introduction 1
Post-traumatic headache (PTH) remains one of the most common and disabling symptoms 2 following traumatic head injury. Defined as a secondary headache that develops within seven days 3 of the head trauma (1) , PTH often shares similar clinical characteristics with primary headaches, 4 in particular migraine and tension-type headache (TTH) (2, 3). Currently, there exists no consensus 5 on how PTH should be treated, primarily due to the poor understanding of its underlying 6 mechanisms, which can be attributed in part to the paucity of well characterized and clinically 7 relevant animal models with strong predictive validity. We recently characterized numerous PTH-8 like pain behaviors in male rats subjected to a mild closed head injury (mCHI) using a weight drop 9 device (4). These include the development of acute cephalic allodynia, deficits in spontaneous 10 exploratory activity and latent sensitization to the headache trigger glyceryl trinitrate (GTN) . 11 Furthermore, these pain behaviors were amenable to acute treatment with sumatriptan as well as 12 repeated administration of an anti-calcitonin-gene-related peptide monoclonal antibody (Anti-13 CGRP mAb) starting immediately after the head injury (4), further strengthening the translational 14 validity and potential utility of this animal model to study mechanisms of PTH. 15 16 Current understanding of PTH symptomatology and possible underlying mechanisms, as gleaned 17 by clinical (3) and preclinical studies (5) are primarily based on findings in male subjects, in part 18 due to the traditionally perceived idea of greater participation of males in activities with increased 19 risk of head injuries and related concussions. However, recent clinical data suggest that females, 20 in particular at adolescent age, have a similar or even higher risk for concussive injuries (6) . 21 Furthermore, females are now thought to have a similar or even increased risk, in particular at 22 young age, of developing of PTH (7) (8) (9) (10) . 23 maintain a homogenous lighting across the arenas (80 lux). The arena was cleaned with a mild 1 detergent and dried to remove odor cues between successive rats. 2 3 Assessment of tactile pain hypersensitivity following mCHI. 4 5 Behavioral tests were performed during the light phase (08:00-15:00). The method was previously 6 used by us and others to study PTH-and migraine-related pain behaviors (4, (16) (17) (18) . Briefly, 7 animals were placed in a transparent flat-bottomed acrylic holding apparatus (20.4 cm x 8.5 cm). 8
The apparatus was large enough to enable to the animals to escape the stimulus. Animals were 9 habituated to the arena for 15 minutes prior to the initial testing. In order to determine if the animals 10 developed pericranial (cephalic) tactile hypersensitivity, the skin region, including the midline area 11 above the eyes and 2 cm posterior, was stimulated with different von Frey (VF) filaments (0.6 g-12 15 g/force) (18011 Semmes-Weinstein Anesthesiometer kit). Development of hind paw 13 hypersensitivity was tested by stimulating, using the VF filaments, the mid-dorsal part of the hind 14 paw. We evaluated changes in withdrawal thresholds, as well as non-reflexive pain responses to 15 the stimulation using a method previously described in this and other headache models (19-21) by 16 recording 4 behavioral responses adapted from Vos et al. (22) as follows: 0) No response: rat did 17 not display any response to stimulation 1) Detection: rat turned its head towards stimulating object 18 and latter is explored usually by sniffing; 2) Withdrawal: rat turned its head away or pulled it 19 briskly away from stimulating object (usually followed by scratching or grooming of stimulated 20 region); 3) Escape/Attack: rat turned its body briskly in the holding apparatus in order to escape 21 stimulation or attacked (biting and grabbing movements) the stimulating object. Starting with the 22 lowest force, each filament was applied 3 times with an intra-application interval of 5 seconds and 23 the behavior that was observed at least twice was recorded. For statistical analysis, the score 24 recorded was based on the most aversive behavior noted. The force that elicited two consecutive 1 withdrawal responses was considered as threshold. To evaluate pain behavior in addition to 2 changes in threshold, for each rat, at each time point, a cumulative pain score was determined by 3 combining the individual scores (0-3) for each one of the VF filaments tested. All tests were 4 conducted and evaluated in a blinded manner. 5 6 mCHI evoked latent sensitization to GTN 7
The development of mechanical hyperalgesia in response to systemic administration of a 8 previously subthreshold dose of the headache trigger glyceryl trinitrate (GTN, 100µg/kg i.p., 9
American Reagents, USA) when animals returned to baseline following mCHI was assessed as 10 described (4, 21). After obtaining pre-GTN baseline cephalic and hind paw VF responses at day 11 29 post mCHI/sham, animals received GTN on day 30 and were assessed for changes in cephalic 12 and hind paw mechanical pain thresholds 4 hours later. 13
Pharmacological treatments 14
Sumatriptan (Tocris, USA) was freshly dissolved in 0.9% saline and administered intra-peritoneal 15 (i.p.) at a dose of 1mg/kg in a volume of 1ml/kg. Drug dose and times of administration were based 16 on the pharmacokinetics of the drugs, studies demonstrating their efficacy in animal and human 17 models of trigeminal pain (16, 23), and our previous data on PTH-like behaviors following mCHI 18 in males (4). Anti-CGRP mAb and its corresponding isotype IgG were provided by TEVA 19 Pharmaceuticals, and formulated in phosphate buffered saline (PBS). mAb and IgG were injected 20 i.p at a dose of 30 mg/kg, immediately after the head injury and every 6 days subsequently up to 21 day 30. This dosing regimen has been shown previously to alleviate PTH-like pain behavior (i.e. cephalic allodynia) following mCHI in male rats (4) and pain behaviors in other chronic migraine 1 models (24). 2
Peripheral blood collection and serum CGRP analysis 3
At multiple time points (baseline and 72h, Day 7, Day 14 post mCHI) rats were lightly anesthetized 4 and placed chest down on a heating blanket. The tail was dipped in warm water for 10 seconds in 5 order to increase vascular flow and swabbed with alcohol. Approximately 300 microliters of blood 6 was collected from the tail vein using a BD Vacutainer Safety-Lok blood collection needle (Becton 7 Dickinson, USA) and placed in a microfuge tube containing 10 microliters of protease inhibitor 8 (Millipore Sigma). Immediately after collection, the blood was placed on ice to coagulate for 30 9 minutes. Following coagulation, blood was centrifuged at 3000g for 10 min at 4 degrees. The 10 serum supernatant was transferred to fresh microfuge tubes, snap frozen on dry ice and stored at -11 80 degrees Celsius. Serum samples were analysed for CGRP levels via a custom ELISA. Briefly, 12 a 96-well plate was coated with a mouse anti-CGRP capture antibody (Bertin Bioreagent) and 13 incubated overnight at 4°C. The coated plate was washed three times with wash buffer (PBS with 14 0.05% Tween 20) and then blocked using the Sword Blocker SBL-501 reagent (Sword 15 Diagnostics) for 1 hour at room temperature. After several washes, serum samples and a range of 16 CGRP standards diluted in Sword Diluent SDI-802 were pipetted into the coated plate with a 17 human anti-CGRP detection antibody (Teva Pharmaceuticals) and incubated at room temperature 18 for 2 hours. After washing the plate, captured CGRP analytes were complexed to a HRP-19 conjugated mouse anti-human antibody (Southern Biotech) at room temperature for 1 hour. 20
Following several washes, Sword detector reagents consisting of a substrate/peroxidase mixture 21 were used according to the manufacturer's instructions. Resonance Raman signals generated using 22 Sword reagents were measured using fluorescence intensity detection at an excitation/emission 1 wavelength of 530nm/730nm using a BioTek Cytation 5 Microplate Reader. 2
Data analyses 3
Statistical analyses were conducted using Graph pad prism (version 8.0). All data are presented as 4 the means ±standard error of the mean. Mechanical pain threshold data, obtained using VF 5 filaments was log-transformed, which is more consistent with a normal distribution (25) . To study 6 time-course changes in open-field behaviour, and responses to mechanical stimuli, data was 7 analysed using a mixed design ANOVA to determine the effects of time and treatment. Data 8 included passed the Brown-Forsythe test, indicating equal variance. We used Fisher's LSD post 9 hoc tests, and correction for multiple comparisons was conducted using the Benjamini and 10
Hochberg false discovery rate (FDR) controlling procedures (26). Responses to GTN were 11 assessed using two-tailed paired t-test. The effects of drug treatment on the changes in nociceptive 12 behaviours were analysed using two-tailed unpaired t-test. Changes in CGRP plasma levels were 13 tested using one-Way Brown-Forsythe ANOVA test. Significant p and q value were set as 0.05. 14 1
mCHI-evoked changes in open-field behavior 2
Previously, we observed that mCHI did not affect the overall distance moved of male rats in an 3 open field, indicating no gross motor deficits, but led to a reduction in rearing activity suggesting 4 deficits in exploratory behavior, potentially due to a mild TBI (4, 27, 28). Here, we observed that 5 females subjected to a similar mCHI protocol also did not exhibit changes in distance moved when 6 tested up to 14 days post mCHI (Time, F4,56 = 2.1, p = 0.1; Treatment, F1,14 = 0.4, p=0.5; Figure  7 1(b)). Similarly, mCHI females also did not exhibit any change in rearing activity (Time, F4,56 = 8 2.4; p = 0.07; Treatment F1,14 = 0.1, p=0.7; Figure 1(c) ) pointing to the possibility of a milder form 9 of TBI when compared to males. The lack of a noticeable decrease in exploratory rearing activity, 10 however, may be due to a lower baseline rearing behavior in our female cohort when compared to 11 the matching male cohort (females; 109.5±8.4 beam breaks/20 min vs males; 167.9 ±12.1 beam 12 breaks/20 min; p < 0.001, unpaired t-test; not shown). Females subjected to mCHI, however, 13 displayed reductions in center zone exploration, indicating increased thigmotaxis (Time, F4,56 = 14 7.9; p < 0.0001; Treatment, F1,14 = 4.63; p < 0.05; Figure 1(d) ). Post-hoc analysis revealed 15 decreased center zone exploration at 2 and 3 days following mCHI (q<0.01 for both) suggesting 16 an acute increase in anxiety-related behaviors, potentially related to mTBI (29, 30) . The increased 17 thigmotaxis response in females was likely a specific sex-dependent response to the mCHI given 18 that males and females exhibited similar pre-mCHI baseline values (29.1±4.2% of time spent in 19 center vs 32.3 ± 2.5 % of time spent in center; p = 0.52, unpaired t-test, not shown). animals). FDR, false discovery rate; mCHI, mild closed-head injury. 10 11
Development of mechanical pain hypersensitivity following mCHI 12
Male rats subjected to mCHI develop cephalic mechanical hypersensitivity that resolves by day 13 14 post mCHI. Here, we observed that females subjected to a similar mCHI protocol, also exhibited 14 decreased cephalic mechanical thresholds when compared to sham animals (Time, F6,129 = 15.3, p 15 < 0.001; Treatment: F1, 27 = 25.8, p < 0.001; Figure 2(b) ). The duration of this allodynic response 16 was, however, longer than we previously observed in males, and was resolved only by day 29 post 17 mCHI. Females subjected to mCHI also exhibited an increase in pain score in response to cephalic 18 mechanical stimulation (Time: F6,131 = 10.3, p<0.0001; Treatment: F1, 27 = 9.3, p < 0.001; Figure 2  19 (C)); this hyperalgesic behavior, however was shorter lasting and resolved by day 14 post mCHI.
As in males, the development of cephalic pain hypersensitivity was not accompanied by 1 extracephalic changes throughout the 29 days observation period (threshold, F6,137 = 8.8, p<0 .001 2 for time; F1,27 = 1.4, p = 0.25 for treatment; pain score, F6,137 = 9.5, p<0.001 for time; F1,27 =1.4, p 3 = 0.24 for treatment, Figures 2(d and e) ). cumulative pain scores at the cephalic (c) and extracephalic (e) regions. Two-way repeated 11 measures ANOVA, followed by post-hoc test between mCHI and sham animals indicate a 12 prolonged decrease in withdrawal thresholds and increase in pain score following mCHI at the 13 cephalic region, but no extracephalic changes. Sham: n=12; mCHI: n=17. * q<0.05, *** q<0.001 14 (FDR-corrected values after Fisher's least significant difference post-hoc test at selected time 15 points vs similar time points in sham control animals). 16 17 18 mCHI-evoked prolonged latent cephalic and extracephalic sensitization to GTN 1 Male rats subjected to mCHI exhibit latent sensitization manifested as a cephalic hyperalgesic 2 response to a subthreshold dose of the headache trigger GTN, after the recovery from the acute 3 hyperalgesic phase (4). Here, we observed latent sensitization in females that was similar with 4 regard to the cephalic response, but also involved the extracephalic region. When compared to 5 baseline values obtained on day 29 post mCHI, administration of GTN on day 30 resulted in 6 cephalic mechanical hypersensitivity (p<0.001, for thresholds and pain scores, Figures 3(b and  7   c) ), an effect that was not observed in sham animals. Similarly, GTN-evoked hind paw 8 hypersensitivity in mCHI females (p < 0.001, for both threshold and pain score (Figures 3(d, and  9 e)), but not in females subjected to a sham procedure. Acute sumatriptan treatment ameliorates mCHI-induced cephalic hypersensitivity, and 1
GTN-evoked cephalic and extracephalic hypersensitivity 2
In males, acute treatment with sumatriptan alleviates the cephalic mechanical hypersensitivity 3 following mCHI, and the cephalic pain hypersensitivity in response to GTN (4). Here, we found 4 that acute sumatriptan treatment in females, at 7 days post-mCHI, exerted a similar anti-5 hyperalgesic effect by decreasing the cephalic pain threshold (p<0.001, Figure 4(b) ), as well as 6 the associated pain response (p <0.01, Figure 4(c) ). Acute sumatriptan treatment was also effective 7 at inhibiting the GTN-evoked decrease in cephalic mechanical pain threshold and increased pain 8 score (p<0.001, p<0.05 respectively, Figures 5(b and c) ). Sumatriptan was also able to inhibit the 9 GTN-evoked decrease in hind paw mechanical pain threshold, and increased pain score (p<0.001, 10 p<0.001, Figure 5 (d and e) ). Early and repeated administration of anti-CGRP mAb does not prevent mCHI-induced 11 cephalic mechanical hypersensitivity, but partially inhibits GTN-evoked pain 12 hypersensitivity in female rats. 13
In males, repeated administration of anti-CGRP mAb, starting immediately following the mCHI, 14 inhibits the cephalic hypersensitivity and the prolonged latent cephalic sensitization to GTN (4). 15
Here, in contrast, when compared to treatment with a control IgG, similar administration of the 16 anti-CGRP mAb in females did not block the decrease in cephalic pain threshold (Time, F3,90 = 17 17.1, p < 0.0001; Treatment: F1, 30 = 0.1, p = 0.7, Figure 6(b) ), or the associated increase in pain 18 score (Time, F3,90 = 41.5, p < 0.0001; Treatment: F1, 30 = 0.7, p = 0.42, Figure. 6(c) ). Anti-CGRP 1 treatment was also less effective in inhibiting the hyperalgesic response to GTN at 30 days 2 following mCHI. When compared to treatment with the control IgG, anti-CGRP mAb inhibited 3 the GTN-evoked decrease in cephalic thresholds (p<0.05, Figure 7(b) ), but not the associated 4 increase in pain score (p = 0.23, Figure 7(c) ). Treatment with the anti-CGRP mAb was also 5 ineffective in inhibiting the GTN-evoked hind paw hypersensitivity, when compared to IgG (p = 6 0.1 for threshold changes; p = 0.36 for pain score changes, Figures 7(d and e) ). von Frey testing of cephalic mechanical pain sensitivity, followed by mCHI. Anti-CGRP mAb or 12 a control IgG were administered immediately after the mCHI and then every 6 days. Two-way 13 repeated measures ANOVA between anti-CGRP and IgG treatments revealed no effect of 14 treatment on the decrease in cephalic withdrawal threshold (b), or the increase in pain score (c). 15
Means±SEM, Anti-CGRP: n=16; control IgG: n=16; *** q<0.001; ### q< 0.001 (FDR-corrected 16
values after Fisher's least significant difference post-hoc test at 3-14 days post mCHI vs baseline 17 for anti-CGRP and IgG respectively). 18 1 Figure 7 : Treatment with anti-CGRP mAb partially inhibits latent sensitization to GTN in mCHI 2 females. (a) Schematic of experimental design. mCHI rats received treatment with anti-CGRP 3 mAb or a control IgG immediately after the mCHI and then every 6 days. GTN-evoked cephalic 4 and extracephalic mechanical pain hypersensitivity was assessed at days 29 (baseline) and day 5 30 (GTN administration). Summary of the GTN-evoked changes in cephalic withdrawal 6 thresholds (b) and pain scores (c). GTN-evoked extracephalic changes are illustrated in (d) and 7 (e). Means±SEM, Anti-CGRP: n=12; IgG: n=12; * p<0.05 unpaired t-test. 8 9 mCHI in female leads to transient increase in serum CGRP levels. 10
Having found a lack of inhibitory effect of the anti-CGRP mAb on the mCHI-evoked pain 11 hypersensitivity and a partial effect on the latent sensitization to GTN in females, we examined 12 serum CGRP levels in females at baseline and up to 14 days following mCHI. Overall, we found 13 time-related increases in the CGRP serum levels following mCHI (W3,18.9 = 4.5, p<0.01). Post-14 1 produced an anti-hyperalgesic effect following mCHI (4). However, we did not detect any time-2 course changes in serum CGRP levels for up to 14 days following mCHI (W3,15.9 = 0.83, p = 3 0.49). 9 corrected values after Fisher's least significant difference post-hoc test of mCHI vs baseline). 10 11
Discussion

12
Building upon our previous work in male rats subjected to mCHI (4), the present study aimed to 13
characterize changes in open-field behavior, and PTH-like pain behaviors following a similar 14 traumatic head injury protocol in female rats. Our data point to key sex differences, including, 15 enhanced pain responses, an acute increase in anxiety-like behavior, and decreased responsiveness 16 to anti-CGRP mAb treatment in females. 17
A key sensory change identified in male subjects suffering from PTH (31), and in male rats 1 subjected to mCHI (4) is the presence of cutaneous cephalic mechanical pain hypersensitivity. The 2 development of cephalic mechanical allodynia is thought to reflect the sensitization of trigeminal 3 pain pathways, a process that contributes to the pain in other types of headache, in particular 4 migraine (32) . Our current data suggests that mCHI in females leads to an enhanced cephalic 5 hyperalgesic response, in particular a much longer duration, when compared to males subjected to 6 a similar head injury protocol. Female sex has been suggested as a key positive predictor for 7 development of , and has been attributed to their higher prevalence of pre-existing 8 headache and migraine (33, 34) . Given that our rats did not encounter any potential headache 9 producing event prior to the mCHI, our findings rather point to other/additional mechanisms, 10 potentially related to increased nociceptive processing at the level of the peripheral and/or the 11 central nervous system in females (14, (36) (37) (38) , in particular facilitation of the process underlying 12 the development of trigeminal central sensitization in response to head trauma. 13
14
Another key finding of the current study was the inability of an early and sustained anti-CGRP 15 mAb treatment to ameliorate the prolonged cephalic mechanical hypersensitivity post-mCHI in 16 females, in contrast to what we previously observed in males (4). Of importance, was the lack of 17 the anti-hyperalgesic effect of the anti-CGRP mAb was despite the elevation of serum CGRP 18 levels post-mCHI, and strongly suggests that the mCHI-evoked cephalic hypersensitivity in 19 females may not involve peripheral CGRP signaling. It is noteworthy that we did not detect a 20 similar increase in serum CGRP levels in males subjected to mCHI , which is in agreement with a 21 previous study that employed a similar mCHI approach (39). The inconsistency between the 22 effectiveness of anti-CGRP mAb treatment in this model and the changes in serum CGRP levels 23 suggests that the latter may be a poor indicator of peripheral CGRP involvement in mediating a 1 headache-like behavior. Our current finding that acute sumatriptan treatment was effective in 2 reducing the cephalic hyperalgesic behavior in mCHI females, as previously reported in males (4), 3 suggests that its therapeutic mode of action in this model may not involve alteration of the 4 peripheral CGRP signaling cascade, and is likely to bypass the processes that is influenced by sex 5 differences, as observed in other rodent models of persistent migraine-like cephalic pain 6 hypersensitivity (36, 40, 41) . 7 8 In addition to the prolonged cephalic hyperalgesic response in mCHI females, the enhanced pain 9 response in females was also manifested by the development of latent sensitization to GTN that 10 involved the cephalic region, as in males, but also an extracephalic hyperalgesic response to GTN, 11 unlike in males. This increased responsiveness of females to GTN is reminiscent of the greater 12 delayed extracephalic hyperalgesia observed in females following systemic administration of GTN 13 at a higher dose, or after peripheral administration of a low dose (41, 42) , and may be linked to a 14 migraine-related mechanism that is influenced by sex differences. In males subjected to mCHI, 15 the development of latent sensitization to GTN involves an immune-related mechanism, linked 16 to mast cells (21). The previous findings that mCHI involves the degranulation of meningeal 17 mast cells (43) and that meningeal mast cell density in females is higher than in males (13), 18 points to the possibility that meningeal mast cells may play a role in the enhanced nociceptive 19 response in females following mCHI, and particularly the prolonged latent sensitization. 20
Our finding in females that early and prolonged treatment with the anti-CGRP mAb was only 21 partially effective in ameliorating the latent cephalic sensitization, unlike in males, suggests that 22 this process may not be fully dependent on peripheral CGRP signaling, and that it is also under the 23 influence of a sex-dependent mechanism. It is noteworthy that the lack or incomplete anti-1 hyperalgesic effect of anti-CGRP mAb treatment in females in this PTH model is in contrast to 2 previous studies of migraine-related behaviors linked to peripheral CGRP signaling, which 3 reported either lack of sex differences (44, 45), or female specific pro-nociceptive effects (14). 4
Taken together, our data points to a potential differential role for peripheral CGRP signaling in the 5 pathophysiology of PTH and migraine at least in females. The possibility that enhanced and 6 persistent secretion of CGRP from injured meningeal afferent endings that innervate the 7 subarachnoid space (i.e. leptomeningeal afferents), and which could not be targeted by peripherally 8 administered mAb, plays a key role in PTH in females should also be considered. 9
10
The finding that sumatriptan treatment was effective in blocking the GTN-evoked extracephalic 11 hypersensitivity, while anti-CGRP mAb was completely ineffective, points to the possibility that 12 a central, rather than peripheral nociceptive process is involved in mediating PTH females. 13
However, sumatriptan may also act peripherally, potentially via a vascular mechanism, to inhibit 14 the GTN-evoked hyperalgesic response (42). Head trauma and associated brain injury give rise to 15 peripheral changes, including altered immune response (46), and additional studies will be 16 required to determine the relative contribution of mCHI-evoked peripheral vs central changes that 17 mediate the enhanced extracephalic response to GTN. 18 19 A potential contributing factor to the enhanced response of females in this head trauma model is 20 their relative smaller size when compared to males at the time of injury. At present we cannot 21 exclude the possibility that the extended duration of the hyperalgesic response and enhanced 22 hyperalgesic responsiveness to GTN we observed in females involved a greater intracranial 23 damage with extended brain injury. However, the lack of changes in open field activity, including 1 exploratory behavior, which agrees with other TBI-related behaviors noted in similar models of 2 head trauma (47) argues against such a possibility. The development of acute anxiety-like behavior 3 (i.e. thigmotaxis) in females, which was not detected previously in mCHI males, could possibly 4 point to an enhanced secondary condition of brain injury (47). However, since increased 5 thigmotaxis is also observed in other pain models (48-50), it may also signify the interdependent 6 relationship between pain and anxiety. The present study did not monitor the estrous cycle or 7 related hormonal changes, which may have influenced the data. However, the variability noted in 8 the post mCHI data in females was reminiscent of that observed in our previous male study, and 9 is in agreement with finding from a large data set of physiological, and behavioral measures (51), 10
suggesting that estrous cycle-related changes in the levels of circulating hormones in females may 11 not play a large role in this model. 12
13
Conclusions:
14
The current study provides preclinical data supporting the notion of sex differences in the 15 mechanisms underlying the development of posttraumatic headache. The data indicates that 16 females develop posttraumatic cephalic pain hypersensitivity for a longer duration, as well as 17 extended latent hypersensitivity to the headache trigger GTN. In addition, our data suggests that 18 the acute PTH-like pain symptoms in females are CGRP-independent, and that the latent 19 sensitization to GTN involves CGRP signaling to a much lesser extent than in males. The observed 20 sex difference in pain response and CGRP involvement may have implication for the mechanisms 21 that link female sex to the increased propensity to develop PTH, and potentially its therapeutic 22 approaches. 23
